| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Across the recent three months, 7 analysts have shared their insights on Iovance Biotherapeutics (NASDAQ:IOVA), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 1 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 3 | 0 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $27.57, a high estimate of $32.00, and a low estimate of $10.00. Highlighting a 5.39% decrease, the current average has fallen from the previous average price target of $29.14.
The perception of Iovance Biotherapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $32.00 | $32.00 |
| Joseph Catanzaro | Piper Sandler | Lowers | Neutral | $10.00 | $19.00 |
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $32.00 | $32.00 |
| Reni Benjamin | JMP Securities | Lowers | Market Outperform | $23.00 | $25.00 |
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $32.00 | $32.00 |
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $32.00 | $32.00 |
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $32.00 | $32.00 |
To gain a panoramic view of Iovance Biotherapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Iovance Biotherapeutics analyst ratings.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Iovance Biotherapeutics displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 12969.75%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Iovance Biotherapeutics's net margin is impressive, surpassing industry averages. With a net margin of -312.16%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Iovance Biotherapeutics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -13.41%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -10.59%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Iovance Biotherapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.11.
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: IOVA
